Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III single-arm intravesical ONCOFID-P-B in BCG-unresponsive bladder carcinoma in situ
2022-001236-28Phase 3Active
- Sponsor
- Fidia Farmaceutici
- Start
- Sep 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Oncofid-P-B in Bladder cancer in situ (CIS) and non-muscle-invasive bladder cancer (NMIBC), sponsored by Fidia Farmaceutici. Primary endpoint: Complete response rate at end of induction. Started Sep 2022; status: active.
02
Drugs
Oncofid-P-B
03
Conditions
Bladder cancer in situ (CIS)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on 2022-001236-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001236-28.